1. Pharmacokinetics of macrolides. Comparison of plasma, tissue and free concentrations with special reference to roxithromycin

   • O. G. Nilsen

   OriginalPaper Pages: S5 - S9

2. Clinical relevance of intracellular and extracellular concentrations of macrolides

   • C. Carbon

   OriginalPaper Pages: S10 - S14

3. Roxithromycin 150 mg b.i.d. versus amoxycillin 500 mg/clavulanic acid 125 mg t.i.d. for the treatment of lower respiratory tract infections in general practice

   • N. C. Karalus
   • J. E. Garrett
   • C. J. Ryan

   OriginalPaper Pages: S15 - S20

4. Pharmacoeconomic evaluation of roxithromycin versus amoxycillin/clavulanic acid in a community-acquired lower respiratory tract infection study

   • W. G. Scott
   • B. C. Cooper
   • H. M. Scott

   OriginalPaper Pages: S21 - S24

5. The overall safety of oral roxithromycin in paediatric clinical studies

   • P. Bégué
   • J. Astruc

   OriginalPaper Pages: S25 - S27

6. Potential role of roxithromycin against theMycobacterium avium complex

   • L. S. Young
   • L. E. Bermudez
   • C. B. Inderlied

   OriginalPaper Pages: S28 - S32

7. Prevention ofPneumocystis carinii pneumonia and of cerebral toxoplasmosis by roxithromycin in HIV-infected patients

   • J. Durant
   • F. Hazime
   • P. Dellamonica

   OriginalPaper Pages: S33 - S38

8. Roxithromycin in the treatment of lyme disease-update and perspectives

   • R. Gasser
   • I. Wendelin
   • W. Klein

   OriginalPaper Pages: S39 - S43

9. Helicobacter pylori: The place of the new macrolides in the eardication of the bacteria in peptic ulcer disease

   • A. Burette
   • Y. Glupczynski

   OriginalPaper Pages: S44 - S52